Headlines about Biohaven Pharmaceutical (NYSE:BHVN) have been trending positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biohaven Pharmaceutical earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.5609858236703 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Biohaven Pharmaceutical (BHVN) Presents At Needham And Company 17th Annual Healthcare Conference – Slideshow (seekingalpha.com)
- Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Canaccord Sees An ‘Intriguing Setup’ In Biohaven Following Reaction To Phase 3 News (msn.com)
- Biohaven Pharmaceutical Target of Unusually High Options Trading (BHVN) (americanbankingnews.com)
- Stock Traders Buy Large Volume of Biohaven Pharmaceutical Put Options (BHVN) (americanbankingnews.com)
Several brokerages recently issued reports on BHVN. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. Canaccord Genuity reissued a “buy” rating and set a $39.00 target price (up previously from $30.00) on shares of Biohaven Pharmaceutical in a research note on Thursday, February 22nd. Needham & Company LLC reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Thursday, February 22nd. Finally, Piper Jaffray reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Monday. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $37.86.
In other Biohaven Pharmaceutical news, insider Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $30.11, for a total value of $1,053,850.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Declan Doogan sold 128,058 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $26.95, for a total value of $3,451,163.10. Following the completion of the sale, the director now directly owns 2,583,289 shares in the company, valued at approximately $69,619,638.55. The disclosure for this sale can be found here. In the last ninety days, insiders sold 788,546 shares of company stock worth $22,729,021.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/29/biohaven-pharmaceutical-bhvn-getting-positive-media-coverage-study-shows/1971875.html.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.